Pompano Beach, Fla., Sept. 2, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products and specialty pharmaceuticals, today announced it will open its first DS Laboratories Hair Loss Clinic in Miami, Florida. Slated to open in the fourth quarter of 2014, the clinic will provide unique therapies and treatment options for patients who desire the most comprehensive approach to treating hair loss. A team of healthcare professionals led by a medical doctor will provide customized solutions with the most advanced proven technologies developed through DS Healthcare’s clinical research to restore a full head of hair.

“We believe no other company offers the kind of comprehensive hair loss treatment and expertise that will be delivered to patients at our DS Laboratories Hair Loss Clinic. Our commitment to innovation has created a growing portfolio of therapies that are not available anywhere else. The clinics are the ideal platform for DS Healthcare to utilize treatment protocols accumulated through years of clinical research. The clinics will leverage the brand awareness of DS Healthcare with an established target customer base,” stated DS Healthcare President and CEO Daniel Khesin.

According to the Washington Post Americans spend $3.5 billion per year in an attempt to treat hair loss.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group’s flagship brand, visit www.dslaboratories.com

WILMINGTON, Mass., Sept. 2, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has sold $1.2 million worth of trace detectors to a customer in the European Union. The units will be deployed for critical infrastructure protection and homeland security.

“We won this contract in a highly competitive environment. The contract win was a result of our trace detectors exceeding the customer’s expectations, particularly when compared to competitive products, as well as the service and support provided by our superior local distributor,” stated Dr. Darryl Jones, Implant Sciences’ Vice President of Global Sales and Marketing.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company’s team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company’s ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, “Polymeric Systems for the Delivery of Anticancer Drugs”. The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn.

“We are pleased to further expand our platform of proprietary drug delivery technologies in preclinical development. CPMA complements our nano-polymer-drug delivery platform, nano-polymer-drug conjugate system (NPDCS), which has already shown promising results in preclinical studies,” stated Rexahn’s CEO, Peter D. Suzdak, Ph.D. “Our drug delivery platforms address a well-recognized need in cancer treatment for drugs that selectively target and kill cancer cells, while leaving healthy cells unharmed. Although numerous widely used FDA-approved anti-cancer drugs offer benefits to patients, in most cases, the efficacy of these drugs can be significantly improved, and their toxic side-effects minimized, if they can be combined with a targeted drug delivery technology to bring the drug directly into cancer cells.”

The CPMA technology platform allows for multiple anti-cancer compounds to be covalently bound to the proprietary polymer backbone and be coupled to a signaling moiety. The signaling moiety directs the bound drug to the cancer cell, thereby bypassing healthy cells leading to enhanced efficacy with the potential for reduced side effects. Once inside the cancer cell the CPMA complex is metabolized yielding the free anticancer compound. Because of its diverse chemical properties, CPMA is highly water soluble which allows water insoluble anti-cancer compounds to be bioavailable through a more effective delivery.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.

“Given that summer months generally have a slower rate of enrollment for clinical trials, our goal was to maintain the enrollment level compared to the three months prior to the summer. In fact, we did better. We continue to add more centers and countries to the study. As we head into the fall, we believe the pace of patient enrollment will further increase,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

About Multikine

Multikine* (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100 clinical centers in about 20 countries.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

To read the entire article and join the discussion please visit the following link: http://www.renewablesbiz.com/article/14/08/all-eyes-boston-will-new-commercial-food-waste-ban-lead-boom-waste-energy

EVEN YEHUDA, Israel, August 7, 2014 /PRNewswire/ —

Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), a clean energy company that develops, manages and owns waste-to-energy projects, announced today a newly published report authored by three U.S. government agencies outlines new federal initiatives to support exponential growth in the private biogas waste-to-energy sector. The Biogas Opportunities Roadmap, published August 1st by the U.S. Department of Agriculture, U.S. Environmental Protection Agency, and U.S. Department of Energy concluded that:

Developing a viable biogas industry in the U.S. can boost the economy and provide a reliable, distributed source of renewable energy while reducing greenhouse gas emissions
2,000 biogas sites operate in the U.S. today, and more than 11,000 additional biogas systems could be deployed to handle organic waste and produce energy and biogas system co-products
Realizing the full potential of the biogas industry will require support from federal agencies, greater investment, expanded markets for biogas and biogas products, and increased R&D
The benefits of biogas systems are clear. The task ahead is to reduce barriers and promote financial opportunities to move forward in developing a robust biogas industry
In the Biogas Opportunities Roadmap, the federal agencies identify programs that will promote biogas utilization and help the private sector voluntarily realize the full potential of biogas systems. These programs include:

Using existing agency programs to leverage over $10 million in research funding
Fostering investments in biogas systems including reviewing government procurement programs for products of biogas systems
Strengthening markets for biogas systems and system products including by modernizing existing Federal incentives
Improving communication and coordination by establishing a Biogas Opportunities Roadmap Working Group that will include participation from DOE and EPA, as well as the dairy and biogas industries
“The potential for biogas to increase renewable energy production, reduce landfill waste, benefit the environment, and spur economic growth in the U.S. is significant. We are very pleased to see the U.S. government publish a report that outlines these benefits and opportunities. Bluesphere is actively working in several U.S. states to develop biogas facilities. We have brought our global expertise in building and operating waste-to-energy facilities to the U.S. market and we’re finding very strong interest in the value proposition we have to offer. We are eager to expand our operations in the U.S. in conjunction with some major partners and to capitalize on biogas opportunities,” stated Bluesphere CEO Shlomi Palas.

Bluesphere has begun design and engineering work, and is scheduled to break ground in 2014 on a 5.2 MW waste-to-energy anaerobic digester in Charlotte, North Carolina. The Company is also developing in a 3.2 MW waste-to-energy project in Rhode Island and has a Memorandum of Understanding to develop a 5.2 MW waste-to-energy project in Massachusetts.

JERUSALEM, August 19, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.”

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visithttp://www.oramed.com

Pompano Beach, Fla., Aug. 15, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced financial results for the three and six months ended June 30, 2014.

.

Net revenues were $3,744,000, up 9% over Q2 2013

.

Gross margins increase to 52% from 48% in Q2 2013

.

Gross profits increase to $1,942,000 up 21% over Q2 2013

.

Net loss narrows 16% to $(633,000) from Q2 2013

Net revenues were $3,744,434 for the three months ended June 30, 2014, an increase of 9.1% over revenues of $3,431,154 for the three months ended June 30, 2013. Revenue growth in the second quarter was driven by double-digit, year-over-year sales growth at the Company’s Mexican subsidiary, as well increased sell-through in foreign markets. Domestic sales declined in the quarter due to $1 million in backorders that were pending completion and shipment prior to the end of the quarter.

Gross margin increased to 51.9% in the second quarter of 2014 from 46.7% in the same quarter of the prior year as a result of improved production efficiencies, improved pricing from suppliers, and cost cutting efforts including reduced payroll. Gross profits were up 21% to $1,941,536 in the second quarter of 2014, as compared to $1,601,086 in the second quarter of 2013. Selling and marketing costs increased by 34% to $1,194,238 in the second quarter of 2014 from $894,366 in the same period last year. General and administrative costs declined by 2% to $1,338,536 in the three months ended June 30, 2014, as compared to $1,369,558 in the same period of 2013. DS Healthcare’s net loss narrowed by 16% to $(633,339) or $(0.04) per basic and diluted share in the second quarter of 2014 from $(757,063) or $(0.06) per basic and diluted share in the same period of 2013.

For the six months ended June 30, 2014 net revenues were $6,429,397, a 13% decline from revenues of $7,392,846 for the six months ended June 30, 2013. Net revenue growth at the Company’s Mexican subsidiary, as well increased sell-through in foreign markets was offset by a decline in domestic sales due to backorders that were pending completion and shipment.

Gross margin increased to 53.3% in the first half of 2014 from 45.7% in the first half of the prior year, as a result of improved production efficiencies, improved cost from suppliers, and cost cutting efforts including payroll. Gross profits were up 1.4% to $3,423,981 in the first half of 2014, as compared to $3,375,769 in the first half of 2013. Selling and marketing costs increased by 31% to $2,164,260 in the six months ended June 30, 2014 from $1,651,364 in the same period last year. General and administrative costs decreased by 7% to $2,672,480 in the first two quarters of 2014, as compared to $2,878,234 in the same period of 2013. DS Healthcare’s net loss increased by 22% to $(1,479,120) or $(0.09) per basic and diluted share in the first half of 2014 from $(1,215,056) or $(0.10) per basic and diluted share in the same period of 2013.

On June 30, 2014 the Company had cash and cash equivalents of $773,055 and working capital of $3,264,514. Total stockholders’ equity on June 30, 2014 was $4,852,418.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has added Centre Hospitalier Universitaire de Québec (CHUQ)’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America. CHUQ is a network of three teaching hospitals affiliated with the medical school of Université Laval and several specialized institutions in Quebec City. CEL-SCI plans to activate additional clinical sites for accelerated patient enrollment in Canada.

The Principal Investigator for CEL-SCI’s Phase III trial at CHUQ is Dr. André Fortin, a radiation oncologist and visiting professor. He is responsible for the research protocols of radiation therapy for the oncology group at CHUQ. Dr. Fortin has extensive expertise in the treatment of cancers using radiation therapy for head and neck, pulmonary, and digestive cancers. He is very involved in clinical research within the department as evidenced by his numerous publications.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. CEL-SCI’s Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients.

“We are adding many additional centers in Canada and the U.S. for the world’s largest Phase III trial in head and neck cancer. This will hopefully keep us on schedule to complete global enrollment with approximately 880 patients by the end of 2015,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

Pompano Beach, Fla., Aug. 6, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today it has signed a distribution agreement with Drogaria Venancio, a leading Rio de Janerio-based pharmacy chain. Drogaria Venancio will sell DS Healthcare’s clinically proven personal care products including its Revita and Spectral hair re-growth and hair care products. DS Laboratories, its flagship line can already be found on retail shelves throughout Rio de Janeiro. Drogaria Venancio operates wholesale distribution centers and premium retail pharmacy locations. Founded in 1979, the pharmacy chain employs 1600 people.

This marks DS Healthcare’s third distribution agreement in Brazil and it’s second in Rio de Janeiro. DS Healthcare’s have already been selling through CSB Drogaria which has two retail pharmacy chains with 85 stores in Rio de Janeiro, as well as in Sao Paulo through the Drogaria Iguatemi pharmacy chain. Retail sales are also growing through DS Healthcare’ Brazilian ecommerce site. According to market research firm Euromonitor, the Brazilian beauty industry generated $42 billion in sales in 2012.

“We are experiencing extremely robust sales growth in Brazil while building strong brand recognition and loyalty for our products. While we are successfully achieving market penetration into two of Brazil’s largest cities, we also intend to expand distribution beyond these metropolitan areas into other regions of the country. In addition, we’ve seen our e-commerce platform that services customers in regions where we have yet to be present, do extremely well, further endorsing our belief that Brazil will be one of our key markets worldwide” stated DS Healthcare President and CEO Daniel Khesin. ”

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group’s flagship brand, visit www.dslaboratories.com